PMID- 37296371
OWN - NLM
STAT- MEDLINE
DCOM- 20240110
LR  - 20240116
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
VI  - 47
IP  - 1
DP  - 2024 Jan
TI  - Femoral bone mineral density at the time of hip fracture is higher in women with 
      versus without type 2 diabetes mellitus: a cross-sectional study.
PG  - 59-66
LID - 10.1007/s40618-023-02122-3 [doi]
AB  - PURPOSE: To compare femoral bone mineral density (BMD) levels in hip-fracture 
      women with versus without type 2 diabetes mellitus (T2DM). We hypothesized that 
      BMD levels could be higher in the women with T2DM than in controls and we aimed 
      to quantify the BMD discrepancy associated with the presence of T2DM. METHODS: At 
      a median of 20 days after the occurrence of an original hip fracture due to 
      fragility we measured BMD by dual-energy x-ray absorptiometry at the 
      non-fractured femur. RESULTS: We studied 751 women with subacute hip fracture. 
      Femoral BMD was significantly higher in the 111 women with T2DM than in the 640 
      without diabetes: mean T-score between-group difference was 0.50, (95% CI from 
      0.30 to 0.69, P < 0.001). The association between the presence of T2DM and 
      femoral BMD persisted after adjustment for age, body mass index, hip-fracture 
      type, neurologic diseases, parathyroid hormone, 25-hydroxyvitamin D and estimated 
      glomerular filtration rate (P < 0.001). For a woman without versus with T2DM, the 
      adjusted odds ratio to have a femoral BMD T-score below the threshold of - 2.5 
      was 2.13 (95% CI from 1.33 to 3.42, P = 0.002). CONCLUSIONS: Fragility fractures 
      of the hip occurred in women with T2DM at a femoral BMD level higher than in 
      control women. In the clinical assessment of fracture risk, we support the 
      adjustment based on the 0.5 BMD T-score difference between women with and without 
      T2DM, although further data from robust longitudinal studies is needed to 
      validate the BMD-based adjustment of fracture risk estimation.
CI  - (c) 2023. The Author(s), under exclusive licence to Italian Society of 
      Endocrinology (SIE).
FAU - Di Monaco, M
AU  - Di Monaco M
AD  - Division of Physical and Rehabilitation Medicine, Osteoporosis Research Center, 
      Presidio Sanitario San Camillo, Fondazione Opera San Camillo, Strada Santa 
      Margherita 136, 10131, Turin, Italy. marco.dimonaco@camilliani.net.
FAU - Castiglioni, C
AU  - Castiglioni C
AD  - Division of Physical and Rehabilitation Medicine, Osteoporosis Research Center, 
      Presidio Sanitario San Camillo, Fondazione Opera San Camillo, Strada Santa 
      Margherita 136, 10131, Turin, Italy.
FAU - Bardesono, F
AU  - Bardesono F
AD  - Division of Physical and Rehabilitation Medicine, Osteoporosis Research Center, 
      Presidio Sanitario San Camillo, Fondazione Opera San Camillo, Strada Santa 
      Margherita 136, 10131, Turin, Italy.
FAU - Freiburger, M
AU  - Freiburger M
AD  - Division of Physical and Rehabilitation Medicine, Department of Surgical 
      Sciences, University of Turin, Turin, Italy.
FAU - Milano, E
AU  - Milano E
AD  - Division of Physical and Rehabilitation Medicine, Osteoporosis Research Center, 
      Presidio Sanitario San Camillo, Fondazione Opera San Camillo, Strada Santa 
      Margherita 136, 10131, Turin, Italy.
FAU - Massazza, G
AU  - Massazza G
AD  - Division of Physical and Rehabilitation Medicine, Department of Surgical 
      Sciences, University of Turin, Turin, Italy.
LA  - eng
PT  - Journal Article
DEP - 20230610
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
SB  - IM
MH  - Humans
MH  - Female
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Bone Density
MH  - Cross-Sectional Studies
MH  - *Hip Fractures/epidemiology/etiology
MH  - Absorptiometry, Photon
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Dual-energy x-ray absorptiometry
OT  - Hip fractures
OT  - Osteoporosis
EDAT- 2023/06/10 15:13
MHDA- 2024/01/10 06:42
CRDT- 2023/06/09 23:31
PHST- 2022/12/15 00:00 [received]
PHST- 2023/05/26 00:00 [accepted]
PHST- 2024/01/10 06:42 [medline]
PHST- 2023/06/10 15:13 [pubmed]
PHST- 2023/06/09 23:31 [entrez]
AID - 10.1007/s40618-023-02122-3 [pii]
AID - 10.1007/s40618-023-02122-3 [doi]
PST - ppublish
SO  - J Endocrinol Invest. 2024 Jan;47(1):59-66. doi: 10.1007/s40618-023-02122-3. Epub 
      2023 Jun 10.